NCT06288893尚未招募2 期
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SHEN211 Tablets in the Treatment of Patients With Mild and Moderate Novel Coronavirus Infection
JKT Biopharma Co., Ltd.1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Change from baseline in SARS-CoV-2 viral load at each time point
研究概览
简要总结
Randomized, double-blind, placebo-controlled, multicenter phase II clinical study of SHEN211 tablets
详细描述
A total of 30 patients with mild to moderate novel coronavirus infection (COVID-19) were enrolled and randomized in a 2:1 ratio to the experimental and placebo groups, and subjects received 5 days of oral administration of SHEN211 or SHEN211 placebo to assess the effectiveness of SHEN211 tablets in the treatment of mild to moderate COVID-19 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
double-blind
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •subjects must be 18 years of age or older at the time of signing the informed consent form;
- •subject has a positive SARS-CoV-2 test result;
- •Subjects have one or more mild and moderate COVID-19 clinical symptoms with a symptom score of ≥ 2 (see Attached Table 2): fever, cough, sore throat or dry throat, nasal congestion or runny nose, fatigue or fatigue, headache, muscle or body pain (or soreness), shortness of breath or dyspnea, nausea, vomiting, diarrhea; Presence of one or more of the following signs/symptoms within 24 hours prior to randomization: fever, cough, sore throat or dry throat, nasal congestion or runny nose, fatigue or fatigue, headache, muscle or body aches (or aches), shortness of breath or dyspnea, nausea, vomiting, diarrhea;
- •subjects need to meet conditions: 1) The first occurrence of COVID-19 symptoms ≤ 3 days from the first administration of investigational product; 2) Samples for the first positive SARS-CoV-2 virus infection assay were ≤ 5 days from the first administration of investigational product; 3) SARS-CoV-2 viral nucleic acid detection Ct value ≤ 30 on the day of the first dose;
- •Subjects (women and men of childbearing age) and their sexual partners are willing to have no fertility plan and voluntarily take effective contraceptive measures and have no sperm donation or egg donation plan from the signing of the informed consent form to 1 month after the last dose of the study drug (see Appendix 6 for the definition and contraceptive measures of women of childbearing age);
- •The subject is able to understand and abide by the procedures and methods of this clinical trial. After full informed consent, the subject voluntarily participates and signs the informed consent form by himself/herself, or has a legal representative who can provide the informed consent form.
排除标准
- •subjects may progress to severe and severe COVID-19 before randomization as judged by the investigator;
- •SpO2 ≤ 93% or PaO2/FiO2 ≤ 300 mmHg, or respiratory rate ≥ 30/minute on sea-level room air;
- •urgent or expected need for nasal high-flow oxygen therapy or noninvasive positive pressure ventilation, invasive mechanical ventilation, or ECMO;
- •known history of active hepatitis (acute or chronic active hepatitis B or C), cirrhosis, or hepatic decompensation (including ascites, variceal bleeding, or hepatic encephalopathy); impaired immune system (including patients who have been treated with immunosuppressive agents for a long time, or patients with progressive or recurrent cancer, or known human immunodeficiency virus infection);
- •Screening ALT or AST > 1.5 times ULN or Cockcroft-Gault defined known current renal impairment as CrCl < 30 mL/min or requiring dialysis (see Appendix 4 for calculation formula);
- •Subjects who have received antiviral drugs (e.g., neltamivir tablets/ritonavir tablets, azvudine tablets, monoprevir capsules, sinotervir tablets/ritonavir tablets, deuterated remidavir hydrobromide tablets, and Chinese herbal medicine/Chinese patent medicine for anti-coronavirus therapy) treatment or prevention within 30 days before randomization;
- •The subject has received SARS-CoV-2 monoclonal antibody therapy or prophylaxis or antiviral therapy (including study treatment) or the subject has received convalescent COVID-19 plasma therapy;
- •the subject has a history of dysphagia or gastrointestinal disease that seriously affects drug absorption (including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, subtotal gastrectomy, etc.);
- •acute attack of chronic respiratory diseases, including bronchial asthma, chronic obstructive pulmonary disease;
- •concurrent influenza at screening, which may interfere with the assessment of response to study intervention based on symptoms, signs, laboratory tests, or imaging indicating a high likelihood of bacterial infection;
- •received any COVID-19 vaccine within 3 months before randomization, or infected with novel coronavirus within 3 months before randomization;
- •Complications requiring surgery before randomization or throughout the study period and major surgery 14 days before randomization, or life-threatening complications within 30 days before randomization as considered by the investigator;
- •Use of the following drugs within 14 days before enrollment: strong cytochrome P453A (CYP3A) inhibitors, strong CYP3A inducers, products containing St. John 's wort (Hypericum perforatum);
- •Participated in other clinical trials or taking experimental drugs within 3 months before randomization;
- •known hypersensitivity to any component used in the formulation of the intervention drug;
- •Pregnant and lactating women;
- •Patients who are judged by the investigator to be inappropriate for participation in this study.
研究组 & 干预措施
Placebo for SHEN211 Tablets
Placebo Comparator
10 subjects randomized to placebo
干预措施: Placebo for SHEN211 Tablets (Procedure)
SHEN211 Tablets
Active Comparator
A total of 20 subjects were randomized to the test group
干预措施: SHEN211 Tablets (Drug)
结局指标
主要结局
Change from baseline in SARS-CoV-2 viral load at each time point
时间窗: Up to day 28
Change from baseline in SARS-CoV-2 viral load at each time point
次要结局
- Time to negative(Up to day 28)
- Time of recovery(Up to day 28)
- Change from baseline in chest CT scan (optional)(Up to day 28)
- Percentage of Subjects Progressed(Up to day 28)
- Time to response(Up to day 28)
- Percentage of subjects with disappearance of clinical symptoms(Up to day 28)
- Percent of Subjects Who Died(Up to day 28)
- Safety Assessment Results(Up to day 28)
- Change in COVID-19 symptom score(Up to day 28)
- Ct value change from baseline(Up to day 28)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in SubjectsNASH - Nonalcoholic SteatohepatitisNCT04505436Hanmi Pharmaceutical Company Limited215
已完成
2 期
Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) PatientsRheumatoid ArthritisNCT03254966Jiangsu HengRui Medicine Co., Ltd.194
终止
2 期
Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee ArthroplastyPrevention of Venous Thrombosis After TKANCT05203705Shanghai Hengrui Pharmaceutical Co., Ltd.64
撤回
2 期
Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured AneurysmsRuptured Intracranial AneurysmSubarachnoid HemorrhageNCT02056574NoNO Inc.
已完成
2 期
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)Hidradenitis SuppurativaNCT05216224Aclaris Therapeutics, Inc.95